Cipla USA Recalls Over 400 Cartons of Cancer Drug Nilotinib Due to Manufacturing Issue

• Cipla USA, Inc, a US-based subsidiary of drugmaker Cipla, is recalling over 400 cartons of its generic anti-cancer medication in the US.
• The recalled drug is Nilotinib Capsules, available in 150 mg and 200 mg strengths.
• The recall, initiated on February 18, is due to "failed tablet/capsule specifications" related to a manufacturing issue.
• It is a Class III voluntary recall, meaning the product is not likely to cause adverse health consequences.
• Nilotinib works by blocking abnormal proteins to stop or slow the spread of cancer cells.